Reviva Pharmaceuticals Holdings, Inc. Interest Expense Nonoperating
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Interest Expense Nonoperating of $2.94 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-12
- Reviva Pharmaceuticals Holdings, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $2.94K, a 38.82% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $6.65K, a 42.75% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was -$5.62K, a 219.30% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $2.60K, a 49.38% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. interest expense nonoperating for fiscal 2025 was $13.40K, a 27.55% decline from fiscal 2024.
- Reviva Pharmaceuticals Holdings, Inc. interest expense nonoperating for fiscal 2024 was $18.50K, a 45.15% decline from fiscal 2023.
- Reviva Pharmaceuticals Holdings, Inc. interest expense nonoperating for fiscal 2023 was $33.73K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.94K 10-Q · filed 2026-08-12 | $9.59K 10-Q · filed 2026-08-12 | $3.97K derived: sum of 3 quarters · filed 2026-08-12 | $6.57K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $6.65K 10-Q · filed 2026-05-13 | $1.03K derived: sum of 2 quarters · filed 2026-05-13 | $3.64K derived: sum of 3 quarters · filed 2026-05-13 | $8.44K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$5.62K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$3.02K derived: sum of 2 quarters · filed 2026-03-30 | $1.78K derived: sum of 3 quarters · filed 2026-08-12 | $13.40K 10-K · filed 2026-03-30 |
| 2025-09-30 | $2.60K 10-Q · filed 2025-11-13 | $7.40K derived: sum of 2 quarters · filed 2026-08-12 | $19.02K 10-Q · filed 2025-11-13 | $23.73K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $4.80K 10-Q · filed 2026-08-12 | $16.42K 10-Q · filed 2026-08-12 | $21.13K derived: sum of 3 quarters · filed 2026-08-12 | $26.27K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $11.62K 10-Q · filed 2026-05-13 | $16.33K derived: sum of 2 quarters · filed 2026-05-13 | $21.48K derived: sum of 3 quarters · filed 2026-05-13 | $26.63K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $4.71K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $9.86K derived: sum of 2 quarters · filed 2026-03-30 | $15.01K derived: sum of 3 quarters · filed 2026-03-30 | $18.50K 10-K · filed 2026-03-30 |
| 2024-09-30 | $5.15K 10-Q · filed 2025-11-13 | $10.30K derived: sum of 2 quarters · filed 2025-11-13 | $13.79K 10-Q · filed 2025-11-13 | $27.10K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $5.15K 10-Q · filed 2025-08-14 | $8.64K 10-Q · filed 2025-08-14 | $21.95K derived: sum of 3 quarters · filed 2025-08-14 | $27.85K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $3.49K 10-Q · filed 2025-05-15 | $16.80K derived: sum of 2 quarters · filed 2025-05-15 | $22.70K derived: sum of 3 quarters · filed 2025-05-15 | $35.46K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $13.31K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-03 | $19.21K derived: sum of 2 quarters · filed 2025-04-03 | $31.97K derived: sum of 3 quarters · filed 2025-04-03 | $33.73K 10-K · filed 2025-04-03 |
| 2023-09-30 | $5.90K 10-Q · filed 2024-11-14 | $18.66K derived: sum of 2 quarters · filed 2024-11-14 | $20.41K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $12.76K 10-Q · filed 2024-08-14 | $20.41K 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |